Or. Admin. Code § 410-121-0420 - DESI Less-Than-Effective Drug List
(1) An October 23, 1981 ruling by District of
Columbia Federal Court directed the Department of Health and Human Services to
stop reimbursement, effective October 30, 1981, under Medicaid and Medicare
Part B for all DESI less-than-effective drugs which have reached the Federal
Drug Administration Notice-of-Opportunity-for-Hearing stage.
(2) In accordance with Section 1903(i)(5) of
the Social Security Act, federal funds participation (FFP) is not available for
drugs deemed Less Than Effective (LTE) or Identical, Related of Similar (IRS)
drugs for which the Food and Drug Administration (FDA) issued a Notice of
Opportunity for a Hearing (NOOH) for all labeled indications. These drugs are
also termed Drug Efficacy Study Implementation (DESI) drugs. Division does not
reimburse for drugs designated as less than effective or drugs identical,
related, or similar to a DESI drug.
(3) A current list of DESI LTE/IRS drugs is
available at
https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/medicaid-drug-rebate-program-data/index.html.
DESI drugs are identified by Covered outpatient Drug (COD) Status of 5 or
6.
(4) The US Food & Drug
Administration (FDA) has the responsibility of determining the DESI status of a
drug product.
Notes
Statutory/Other Authority: ORS 413.042 & 414.325
Statutes/Other Implemented: ORS 414.065
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.